Tag: Brentuximab Vedotin

Antibody–drug conjugates (ADCs) have transformed targeted cancer therapy by enabling the selective delivery of cytotoxic agents to tumor cells, sparing healthy tissue. The design of ADCs allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently considered the most promising drug classes in oncology, with ongoing efforts to expand their use for non-oncological indications and in combination therapies.

Detailed overall survival (OS) results from the ongoing, randomized, double-blind, multicenter Phase 3 ECHELON-3 study (NCT04404283) investigating brentuximab vedotin (Adcetris®; Pfizer*/Takeda) in combination with...

ASCO 2024: A More Effective Treatment Combination for Hodgkin Lymphoma

Updated efficacy and safety results from Part C of a phase 2 single-arm trial (SGN35-027; ClinicalTrials.gov identifier: NCT03646123; EudraCT 2020-004027-17) evaluating brentuximab vedotin (Adcetris®; Seagen/Takeda)* in combination with the PD-1 inhibitor nivolumab (Opdivo®; Bristol-Myers Squibb) and standard chemotherapy agents doxorubicin (Adriamycin®) and dacarbazine (DTIC-Dome®/Imidazole) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL).

Compared to Brentuximab Vedotin, Nivolumab Reduces Risk of Disease Progression in Untreated Hodgkin Lymphoma

Pfizer and Seagen have entered into a definitive merger agreement under which Pfizer will acquire Seagen for US $229 in cash per Seagen share...

Antibody-drug conjugates have achieved commercial success over the last 10 years with 15 therapies launched globally to date, including 11 with U.S. FDA approval, and two biosimilars. With their ability to direct highly potent cytotoxic payloads selectively to target cells, ADCs offer the prospect of more precise treatments and a reduction in off-target effects.

Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...

Presentations discussing brentuximab vedotin (Adcetris®; Seagen/Takeda) presented during the 62nd American Society of Hematology (ASH) Annual, Meeting, and Exposition, held virtually from December 5...

During the upcoming 35th annual meeting of the Society for Immunotherapy of Cancer’s (SITC) being held November 9-14, 2020, Seagen (previously known as Seattle...